Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML.

Treatment with any of the agents as a monotherapy showed a trend toward increased survival time (median survival of 62 and 59.5 days for mAb or A2ARi, respectively), whereas the combination caused a significant increase in median survival time (69 days) over both immunoglobulin G (IgG) + Mock (58 days) and any of the treatments alone ( Fig. 6J ), supporting a favorable additive effect on survival by blocking different nodes of the adenosine signaling pathway.

also in 53,322 other papers